Nabla Bio

Nabla Bio is an AI-driven therapeutics discovery platform that uses its proprietary Joint Atomic Model (JAM) to design antibodies and protein-based drugs entirely from computational input. JAM operates similarly to how a language model responds to text queries — given a molecular query specifying a target protein's desired binding properties, JAM generates novel antibody sequences from scratch that satisfy those constraints, without starting from an existing antibody scaffold. The company maintains what it describes as probably the fastest feedback loop in the antibody design industry, with a design-to-laboratory-testing turnaround of three to four weeks. JAM's demonstrated capabilities include double-digit success rates in de novo design across a wide range of targets, including picomolar-affinity binders to G protein-coupled receptors (GPCRs) in zero-shot settings — one of the most technically demanding classes of drug targets due to their transmembrane structure. The platform delivers functional antibodies including GPCR agonists, multispecific biologics, and receptor decoys, with preclinical data showing favorable pharmacokinetics, pharmacodynamics, and low immunogenicity in non-human primates. In October 2025, Nabla Bio signed its second multi-year collaboration with Takeda Pharmaceutical worth potential payments exceeding $1 billion, building on a first partnership begun in 2022 and deploying JAM across Takeda's early-stage pipeline. In December 2025, Nabla Bio announced JAM-2, an updated model incorporating expanded experimental datasets and scaled test-time compute. First-in-human data from AI-designed Nabla molecules is anticipated within one to two years from the most advanced pipeline programs. The company's wet-lab integration means computational designs feed directly into in-house experimental validation without the handoff delays common in external CRO models. Nabla Bio's platform is not designed for general biotech workflows or small-molecule drug discovery. Teams working outside antibody and biologic therapeutics — or organizations without early-stage drug development programs requiring novel target engagement — will find the platform's specialization limits its applicability outside its core use case.

Nabla Bio is an AI drug discovery platform that uses its Joint Atomic Model to design antibodies and protein therapeutics de novo, targeting GPCRs, ion channels, and complex multispecific biologics.

Nabla Bio is widely used by professionals, developers, marketers, and creators to enhance their daily work and improve efficiency.

Nabla Bio is an AI Tool purpose-built for de novo protein therapeutic design, using its JAM foundation model to generate functional antibodies and biologics against difficult targets like GPCRs and ion channels. The Takeda partnership validates the platform's commercial readiness, and JAM-2's release in late 2025 extends its design space to multispecific and multimodal therapeutic formats. Access is through direct partnership engagement rather than a self-serve model, making Nabla Bio a platform for organizations with active drug discovery pipelines rather than research exploration.

It is suitable for beginners as well as professionals who want to streamline their workflow and save time using advanced AI capabilities.